In a phase two study involving 12 patients with R/R ALK+ ALCL, crizotinib monotherapy resulted in a remarkable ORR of 83.3%, with 7 patients (58.3%) achieving complete response (173). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.